1. Treatment of agitation following traumatic brain injury: A review of the literature
- Author
-
Shree Bhalerao, Natasha Bollegala, Jennifer Kim, Shannon Tursanski, Theresa Cook, Matthew Levy, Andrea Berson, Sanjeev Sockalingam, Anshu Rajput, Chris Feng, Nupura Krishnadev, and Eva Seto
- Subjects
medicine.medical_specialty ,Traumatic brain injury ,Antiandrogens ,medicine.medical_treatment ,Adrenergic beta-Antagonists ,MEDLINE ,Physical Therapy, Sports Therapy and Rehabilitation ,Buspirone ,chemistry.chemical_compound ,medicine ,Humans ,Limited evidence ,Intensive care medicine ,Psychomotor Agitation ,Rehabilitation ,Aggression ,business.industry ,Lithium carbonate ,medicine.disease ,nervous system diseases ,chemistry ,Brain Injuries ,Neurology (clinical) ,medicine.symptom ,business ,Central Nervous System Agents ,medicine.drug - Abstract
Agitation, restlessness, and aggression are frequent neurobehavioural sequelae in the early stages of recovery from traumatic brain injury (TBI). These behavioural symptoms disrupt patient care and impede rehabilitation efforts. We review the current literature (1985 onwards) examining the pharmacological management of post-TBI agitation in both acute and post-acute conditions. This article will assess the evidence for the use of selected alkylphenols, benzodiazepines, estrogens, antiandrogens, neuroleptics/antipsychotics, antidepressants, anti-Parkinsonian agents, antipsychotics, anticonvulsants, lithium carbonate, buspirone, beta-blockers, and psychostimulants in agitated TBI survivors. Review of the literature suggests that there is limited evidence to accurately guide clinicians in the management of this patient population.
- Published
- 2005
- Full Text
- View/download PDF